Should low high-density lipoprotein cholesterol (HDL-C) be treated?

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 28, Issue 3, 2014, Pages 353-368

  Toth, Peter P ^a,b   Barylski, Marcin ^c   Nikolic, Dragana ^d   Rizzo, Manfredi ^d,e   Montalto, Giuseppe ^d   Banach, Maciej ^c  

^a CGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY OF PALERMO   (Italy)

^e Euro Mediterranean Institute of Science and Technology   (Italy)

Author keywords

coronary artery disease; fibrate; high density lipoproteins; low density lipoproteins; niacin; reverse cholesterol transport; statin; thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANACETRAPIB; EVACETRAPIB; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PIOGLITAZONE; TORCETRAPIB;

ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BIOLOGICAL FUNCTIONS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY STENT; DEATH; DISEASE ASSOCIATION; DISEASE COURSE; EPIDEMIOLOGICAL MONITORING; HEALTH STATUS INDICATOR; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; MEDICATION THERAPY MANAGEMENT; META ANALYSIS (TOPIC); MONOTHERAPY; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; FEMALE; MALE; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; FEMALE; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NIACIN; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84901367551     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2013.11.002     Document Type: Review

References (104)

1. P.P. Toth High-density lipoprotein and cardiovascular disease Circulation 109 2004 1809 1812
2. B.F. Voight, G.M. Peloso, and M. Orho-Melander et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
3. P.P. Toth, P.J. Barter, and R.S. Rosenson et al. High-density lipoproteins: a consensus statement from the National Lipid Association J Clin Lipidol 7 5 2013 484 525
4. W.P. Castelli, J.T. Doyle, and T. Gordon et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study Circulation 55 1977 767 772
5. N.E. Miller, D.S. Thelle, and O.H. Forde et al. The Tromsø heart-study. High-density lipoprotein and coronary heart disease: a prospective case-control study Lancet 1 1977 965 968
6. G. Assmann, P. Cullen, and H. Schulte The Münster Heart Study (PROCAM). Results of follow-up at 8 years Eur Heart J 19 Suppl. A 1998 A2 A11
7. M.T. Cooney, A. Dudina, and D. De Bacquer et al. SCORE investigators. HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk Atherosclerosis 206 2009 611 616
8. G. Walldius, I. Jungner, and I. Holme et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study Lancet 358 2001 2026 2033
9. R. Frikke-Schmidt, B.G. Nordestgaard, and M.C. Stene et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease JAMA 299 2008 2524 2532
10. R.R. Huxley, F. Barzi, and T.H. Lam et al. Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease. An individual participant data meta-analysis of 23 studies in the Asia-Pacific region Circulation 124 2011 2056 2064
11. Emerging Risk Factors Collaboration E. Di Angelantonio, N. Sarwar, and P. Perry et al. Major lipids, apolipoproteins, and risk of vascular disease JAMA 2009 302 1993-2000
12. D.R. Jacobs, I.L. Mebane, and S.I. Bangdiwala et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women, follow-up study of the Lipid Research Clinics Prevalence Study Am J Epidemiol 131 1990 32 47
13. W.P. Castelli Cholesterol and lipids in the risk of coronary artery disease-the Framingham Heart Study Can J Cardiol 4 1988 5A 10A
14. W.P. Castelli, R.J. Garrison, and P.W. Wilson et al. Incidence of coronary heart disease and lipoprotein cholesterol level JAMA 256 1986 2835 2838
15. D.J. Gordon, J.L. Probstfield, and R.J. Garrison et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
16. A. Kitamura, H. Iso, and Y. Naito et al. High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men Circulation 89 1994 2533 2539
17. M.J. Stampfer, F.M. Sacks, and S. Salvini et al. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction N Engl J Med 325 1991 373 381
18. P. Barter, A.M. Gotto, and J.C. LaRosa et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 13 2007 1301 1310
19. E.M. deGoma, N.J. Leeper, and P.A. Heidenreich Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol J Am Coll Cardiol 51 2008 49 55
20. H. Jafri, A.A. Alsheikh-Ali, and R.H. Karas Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk Ann Intern Med 153 2010 800 808
21. P.M. Ridker, J. Genest, and S.M. Boekholdt et al. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
22. B.M. Psaty, M. Anderson, and R.A. Kronmal et al. The association between lipid levels and the risks of incident myocardial infarction, stroke, and total mortality, the Cardiovascular Health Study J Am Geriatr Soc 52 10 2004 1639 1647
23. R.L. Sacco, R.T. Benson, and D.E. Kargman et al. High-density lipoprotein cholesterol and ischemic stroke in the elderly. The Northern Manhattan Stroke Study JAMA 285 2001 2729 2735
24. A.W.E. Weverling-Rijnsburger, I.J. Jonkers, and E. van Exel et al. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age Arch Intern Med 163 2003 1549 1554
25. M.C. Corti, J.M. Guralnik, and M.E. Salive et al. HDL-C predicts coronary heart disease mortality in older persons JAMA 274 1995 575 577
26. S.H. Johnsen, E.B. Mathiesen, and E. Fosse et al. Elevated high-density lipoprotein cholesterol levels are protective against plaque progression, a follow-up study of 1952 persons with carotid atherosclerosis the Tromso study Circulation 112 4 2005 498 504
27. K. Ishikawa, S. Tani, and I. Watanabe et al. Effect of pravastatin on coronary plaque volume Am J Cardiol 92 2003 975 977
28. R.M. Wolfram, H.B. Brewer, and Z. Xue et al. Impact of low high-density lipoproteins on in-hospital events and one-year clinical outcomes in patients with non-ST-elevation myocardial infarction acute coronary syndrome treated with drug-eluting stent implantation Am J Cardiol 98 2006 711 717
29. J.M. Foody, F.D. Ferdinand, and G.L. Pearce et al. HDL cholesterol level predicts survival in men after coronary artery bypass graft surgery: 20-year experience from the Cleveland Clinic Foundation Circulation 102 2000 III90-4
30. W.A. van der Steeg, I. Holme, and S.M. Boekholdt et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein a-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies J Am Coll Cardiol 51 2008 634 642
31. S.J. Robins, A. Lyass, and J.P. Zachariah et al. Insulin resistance and the relationship of a dyslipidemia to coronary heart disease: the Framingham Heart Study Arterioscler Thromb Vasc Biol 31 2011 1208 1214
32. P.P. Toth, D. Potter, and E. Ming Prevalence of lipid abnormalities in the United States: The National Health and Nutrition Examination Survey 2003-2006 J Clin Lipidol 6 4 2012 325 330
33. E.S. Ford, W.H. Giles, and W.H. Dietz Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey JAMA 287 2002 356 359
34. H. Ghandehari, S. Kamal-Bahl, and N.D. Wong Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004 Am Heart J 156 2008 112 119
35. A. Gatti, M. Maranghi, and S. Bacci et al. Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes Diabetes Care 32 2009 1550 1552
36. J. Morton, S. Zoungas, and Q. Li et al. Low HDL cholesterol and the risk of diabetic nephropathy and retinopathy: results of the ADVANCE study Diabetes Care 35 2012 2201 2206
37. A.A. Alsheikh-Ali, J.L. Lin, and P. Abourjaily et al. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol Am J Cardiol 100 2007 1499 1501
38. R.B. Ervin Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index: United States, 2003-2006 Natl Health Stat Report 13 2009 1 7
39. C.C. Cowie, K.F. Rust, and E.S. Ford et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006 Diabetes Care 32 2009 287 294
40. E. Bruckert, M. Baccara-Dinet, and F. McCoy et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients Curr Med Res Opin 21 2005 1927 1934
41. R.W. Mahley, J. Pepin, and K.E. Palaoglu et al. Low levels of high-density lipoproteins in Turks, a population with elevated hepatic lipase. High-density lipoprotein characterization and gender-specific effects of apolipoprotein E genotype J Lipid Res 41 2000 1290 1301
42. T. Vaisar, S. Pennathur, and P.S. Green et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL J Clin Invest 117 2007 746 756
43. P.P. Toth Reverse cholesterol transport: high-density lipoprotein's magnificent mile Curr Atheroscler Rep 5 2003 386 393
44. P.P. Toth Activation of intracellular signaling systems by high-density lipoproteins J Clin Lipidol 4 2010 376 381
45. J.R. Nofer, B. Kehrel, and M. Fobker et al. HDL and arteriosclerosis: beyond reverse cholesterol transport Atherosclerosis 161 2002 1 16
46. J.R. Nofer, M. Walter, and B. Kehrel et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate Arterioscler Thromb Vasc Biol 18 1998 861 869
47. P.P. Toth High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects Dis Mon 47 2001 369 416
48. M.A. Fryirs, P.J. Barter, and M. Appavoo et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion Arterioscler Thromb Vasc Biol 30 2010 1642 1648
49. A.V. Khera, M. Cuchel, and M. de la Llera-Moya et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
50. S. Yamamoto, P.G. Yancey, and T.A. Ikizler et al. Dysfunctional high-density lipoprotein in patients on chronic hemodialysis J Am Coll Cardiol 60 2012 2372 2379
51. B.J. Ansell, G.C. Fonarow, and A.M. Fogelman High-density lipoprotein: is it always atheroprotective? Curr Atheroscler Rep 8 2006 405 411
52. A.P. van de Woestijne, Y. van der Graaf, and A.-H. Liem et al. Low HDL-cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication J Am Coll Cardiol 2013 10.1016/j.jacc.2013.04.101
53. S. Acharjee, W.E. Boden, and P.M. Hartigan et al. Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE trial J Am Coll Cardiol 2013 10.1016/j.jacc.2013.07.051
54. M. Briel, I. Ferreira-Gonzalez, and J.J. You et al. Association between change in high-density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis BMJ 338 2009 b92
55. R.S. Birjmohun, B.A. Hutten, and J.J. Kastelein et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials J Am Coll Cardiol 45 2005 185 197
56. P.M. Lavigne, and R.H. Karas The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression J Am Coll Cardiol 61 2013 440 446
57. S.J. Nicholls, E.M. Tuzcu, and I. Sipahi et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis JAMA 297 2007 499 508
58. C.M. Ballantyne, J.S. Raichlen, and S.J. Nicholls et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden Circulation 117 2008 2458 2466
59. B. Brown, X. Zhao, and M. Cheung Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence J Clin Lipidol 1 2007 88 94
60. G. Martin, H. Duez, and C. Blanquart et al. Statin-induced inhibition of the Rho-signaling pathway activates PPAR-α and induces HDL apoA-I J Clin Invest 107 2001 1423 1432
61. E.J. Schaefer, and B.F. Asztalos The effects of statins on high-density lipoproteins Curr Atheroscler Rep 8 2006 41 49
62. J.R. Downs, M. Clearfield, S. Weis for the AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels JAMA 279 1998 1615 1622
63. A.M. Gotto Jr., E. Whitney, and E.A. Stein et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 5 2000 477 484
64. C.J. Packard, I. Ford, M. Robertson for the PROSPER Study Group Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) Circulation 112 20 2005 3058 3065
65. C.M. Ballantyne, J.A. Herd, and L.L. Ferlic et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy Circulation 99 6 1999 736 743
66. R.S. Birjmohun, B.A. Hutten, and J.J.P. Kastelein et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds. A meta-analysis of randomized controlled trials J Am Coll Cardiol 45 2005 185 197
67. J.C. Fruchart Peroxisome proliferator-activated receptor-a activation and high-density lipoprotein metabolism Am J Cardiol 88 Suppl 2001 24N 29N
68. C.-G. Ericsson, A. Hamsten, and J. Nilsson et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male post infarction patients Lancet 347 1996 849 853
69. M.H. Frick, M. Syvänne, and M.S. Nieminen et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol Circulation 96 1997 2137 2143
70. M. Jun, C. Foote, and J. Lv et al. Effects of fibrates on cardiovascular out-comes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
71. M.H. Frick, O. Elo, and K. Haapa et al. Helsinki Heart Study, primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N Engl J Med 317 1987 1237 1245
72. H.B. Rubins, S.J. Robins, D. Collins for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
73. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
74. A. Tenenbaum, M. Motro, and E.Z. Fisman et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome Arch Intern Med 165 2005 1154 1160
75. I. Goldenberg, M. Benderly, and R. Sidi et al. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial) Am J Cardiol 103 2009 41 45
76. I. Goldenberg, V. Boyko, and A. Tennenbaum et al. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial Arch Intern Med 169 2009 508 514
77. R. Scott, R. O'Brien, G. Fulcher FIELD Study Investigators Effects of fenofibrate treatment on cardiovascular disease in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
78. ACCORD Study Group H.N. Ginsberg, M.B. Elam, and L.C. Lovato et al. Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
79. S. Tunaru, J. Kero, and A. Schaub et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat Med 9 2003 352 355
80. T. Rubic, M. Trottmann, and R.L. Lorenz Stimulation of CD36 and the key effector of reverse cholesterol transport ATP binding cassette A1 in monocytoid cells by niacin Biochem Pharmacol 67 2004 411 419
81. The Coronary Drug Project Research Group Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
82. G. Brown, J.J. Albers, and L.D. Fisher et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1298
83. E.J. Whitney, R.A. Krasuski, and B.E. Personius et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events Ann Intern Med 142 2005 95 104
84. B.G. Brown, X.Q. Zhao, and A. Chait et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592
85. A.J. Taylor, L.E. Sullenberger, and H.J. Lee et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517
86. A.J. Taylor, H.J. Lee, and L.E. Sullenberger The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3 Curr Med Res Opin 22 2006 2243 2250
87. A.J. Taylor, T.C. Villines, and E.J. Stanek et al. Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
88. W.E. Boden, J.L. Probstfield, and T. Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
89. http://www.ctsu.ox.ac.uk/∼thrive/.
90. S. Murthy, E. Born, and S.N. Mathur et al. Liver-X-receptor-mediated increase in ATP-binding cassette transporter A1 expression is attenuated by fatty acids in CaCo-2 cells: effect on cholesterol efflux to high-density lipoprotein Biochem J 377 2004 545 552
91. R.B. Goldberg, D.M. Kendall, and M.A. Deeg et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia Diabetes Care 28 2005 1547 1554
92. J.P. van Wijk, E.J. de Koning, and E.P. Martens et al. Thiazolidinediones and blood lipids in type 2 diabetes Arterioscler Thromb Vasc Biol 23 2003 1744 1749
93. T. Mazzone, P.M. Meyer, and S.B. Feinstein Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial JAMA 296 2007 2572 2581
94. S.E. Nissen, S.J. Nicholls, and K. Wolski et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial JAMA 299 2008 1561 1573
95. J.A. Dormandy, B. Charbonnel, and D.J. Eckland et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in MacroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289
96. P.J. Barter, M. Caulfield, M. Eriksson ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
97. J.J. Kastelein, S.I. van Leuven, L. Burgess RADIANCE 1 Investigators Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
98. M.L. Bots, F.L. Visseren, G.W. Evans RADIANCE 2 Investigators Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double blind trial Lancet 370 2007 153 160
99. G.G. Schwartz, A.G. Olsson, M. Abt dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 2089 2099
100. R. Krishna, M.S. Anderson, and A.J. Bergman et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two doubleblind, randomised placebo-controlled phase I studies Lancet 370 2007 1907 1914
101. C.P. Cannon, S. Shah, and H.M. Dansky et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
102. Clinical trial.gov REVEAL: randomized evaluation of the effects of anacetrapib through Lipid-modification 2010 http://clinicaltrials.gov/ct2/show/ NCT01252953
103. S.J. Nicholls, H.B. Brewer, and J.J. Kastelein et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 2011 2099 2109
104. http://clinicaltrials.gov/show/NCT01687998.